Byrgazov, Konstantin <br/><br/>
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.  [electronic resource] 

 -  Haematologica  01 2018 
 - e10-e12 p.  digital 
<br/><br/> Publication Type: Letter; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1592-8721 
<br/><br/><label>Standard No.: </label>10.3324/haematol.2017.176347  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alleles<br/>Amino Acid Substitution<br/>Antineoplastic Agents--pharmacology<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm--genetics<br/>Fusion Proteins, bcr-abl--genetics<br/>Gene Expression<br/>Humans<br/>Imidazoles--pharmacology<br/>Mutation<br/>Pharmacogenomic Testing<br/>Pharmacogenomic Variants<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyridazines--pharmacology